Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Erratum (v24,p2220)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seidman, A. D.
Right arrow Articles by Norton, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seidman, A. D.
Right arrow Articles by Norton, L.

Journal of Clinical Oncology, Vol 16, 3353-3361, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

AD Seidman, CA Hudis, J Albanel, W Tong, I Tepler, V Currie, ME Moynahan, M Theodoulou, M Gollub, J Baselga and L Norton
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. seidman@mskcc.org

PURPOSE: To evaluate the efficacy and toxicity of paclitaxel administered as a 1-hour infusion on weekly basis, without interruption, to patients with metastatic breast cancer who had received prior therapy. PATIENTS AND METHODS: Thirty patients with metastatic breast cancer received sustained weekly paclitaxel therapy at an initial dose of 100 mg/m2 until disease progression. Prior therapy included adjuvant only (n=17), metastatic only (n=7), or both (n=6). Eighteen patients had received prior anthracycline therapy, 12 of whom had demonstrated progression of disease within 12 months of it. All patients were assessable for efficacy; 29 patients were assessable for toxicity. Pharmacokinetic studies of paclitaxel were also performed. RESULTS: A total of 469 weekly paclitaxel infusions were administered to 30 patients (median, 14 infusions/patient). The median delivered dose-intensity was 91 mg/m2/wk (range, 80 to 108). The overall response rate was 53% (95% confidence interval [CI], 34% to 72%), with 10% complete responses (CRs) and 43% partial responses (PRs). Median response duration was 7.5 months (range, 2 to 11+). Responses were observed in nine of 18 (50%) patients with prior anthracycline therapy, including six of 12 (50%) with disease progression on anthracycline within 1 year (three of four within 6 months). Therapy was well tolerated and remarkable for a lack of overall and cumulative myelosuppression. Grade 3/4 neutropenia occurred in four patients; febrile neutropenia was not observed. Peripheral neuropathy prohibited dose escalation above 100 mg/m2, and grade 3 neuropathy was observed in two of 21 patients at < or = 100 mg/m2. CONCLUSION: Weekly paclitaxel therapy is active and well tolerated in patients with metastatic breast cancer. Weekly therapy should be considered as a current clinical option for these patients and should be incorporated into future comparative clinical trials.


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
J. Matsubara, Y. Shimada, A. Takashima, D. Takahari, Y. Hirashima, N. T. Okita, T. E. Nakajima, K. Kato, T. Hamaguchi, Y. Yamada, et al.
A Phase I Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel (FLTAX) as First-line Therapy for Advanced Gastric Cancer
Jpn. J. Clin. Oncol., August 1, 2008; 38(8): 540 - 546.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Gonzalez-Angulo and G. N. Hortobagyi
Optimal Schedule of Paclitaxel: Weekly Is Better
J. Clin. Oncol., April 1, 2008; 26(10): 1585 - 1587.
[Full Text] [PDF]

Home page
 JCOHome page
A. D. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss, P. K. Marcom, G. Gipson, H. Burstein, D. Lake, C. L. Shapiro, et al.
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
J. Clin. Oncol., April 1, 2008; 26(10): 1642 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. H. Kim, K. Yamaguchi, Y.-J. Bang, H. Takiuchi, W. K. Kang, A. Sato, Y.-K. Kang, J. Sakamoto, C. Abe, and Y. Sakata
Phase II Study of Biweekly Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Gastric Cancer: Korea Japan Collaborative Study Group Trial
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym054v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Ilson, R. Wadleigh, L. Leichman, and D. Kelsen
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
Ann. Onc., May 1, 2007; 18(5): 898 - 902.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al.
Second consensus on medical treatment of metastatic breast cancer
Ann. Onc., February 1, 2007; 18(2): 215 - 225.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. Blum, E. C. Dees, A. Chacko, L. Doane, S. Ethirajan, J. Hopkins, R. McMahon, S. Merten, A. Negron, M. Neubauer, et al.
Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer
J. Clin. Oncol., September 20, 2006; 24(27): 4384 - 4390.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Lee, J. A. Low, E. Croarkin, R. Parks, A. W. Berman, N. Mannan, S. M. Steinberg, and S. M. Swain
Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone
J. Clin. Oncol., May 1, 2006; 24(13): 2084 - 2091.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Lee and S. M. Swain
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
J. Clin. Oncol., April 1, 2006; 24(10): 1633 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. E. Broker, F. Y.F.L. de Vos, C. J. van Groeningen, B. C. Kuenen, H. E. Gall, M. H. Woo, M. Voi, J. A. Gietema, E. G.E. de Vries, and G. Giaccone
Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity.
Clin. Cancer Res., March 15, 2006; 12(6): 1760 - 1767.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Di Costanzo, S. Gasperoni, P. Papaldo, D. Bilancia, L. Manzione, E. Landucci, F. Mazzoni, F. Cognetti, and On behalf of the Gruppo Oncologico Italiano di Ric
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL
Ann. Onc., January 1, 2006; 17(1): 79 - 84.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Eniu, F. M. Palmieri, and E. A. Perez
Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer
Oncologist, October 1, 2005; 10(9): 665 - 685.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Green, A. U. Buzdar, T. Smith, N. K. Ibrahim, V. Valero, M. F. Rosales, M. Cristofanilli, D. J. Booser, L. Pusztai, E. Rivera, et al.
Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
J. Clin. Oncol., September 1, 2005; 23(25): 5983 - 5992.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Hudis
Testing Chemotherapy for Breast Cancer: Timing Is Everything
J. Clin. Oncol., August 20, 2005; 23(24): 5434 - 5436.
[Full Text] [PDF]

Home page
 The OncologistHome page
L. Norton
Conceptual and Practical Implications of Breast Tissue Geometry: Toward a More Effective, Less Toxic Therapy
Oncologist, June 1, 2005; 10(6): 370 - 381.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Del Mastro, F. Perrone, L. Repetto, L. Manzione, V. Zagonel, L. Fratino, D. Marenco, M. Venturini, E. Maggi, C. Bighin, et al.
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
Ann. Onc., February 1, 2005; 16(2): 253 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Briasoulis, G. Pentheroudakis, V. Karavasilis, E. Tzamakou, D. Rammou, and N. Pavlidis
Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors
Ann. Onc., October 1, 2004; 15(10): 1566 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Kikuchi, K. Yamazaki, I. Kinoshita, H. Asahina, M. Imura, E. Kikuchi, J. Konishi, N. Shinagawa, H. Oki, H. Dosaka-Akita, et al.
Phase I Trial of Carboplatin and Weekly Paclitaxel in Patients With Advanced Non-small-cell Lung Cancer
Jpn. J. Clin. Oncol., September 1, 2004; 34(9): 505 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tabernero, M. A. Climent, A. Lluch, J. Albanell, J. B. Vermorken, A. Barnadas, A. Anton, C. Laurent, J. I. Mayordomo, N. Estaun, et al.
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
Ann. Onc., September 1, 2004; 15(9): 1358 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. T. Dang, G. M. D'Andrea, M. E. Moynahan, M. N. Dickler, A. D. Seidman, M. Fornier, M. E. Robson, M. Theodoulou, D. Lake, V. E. Currie, et al.
Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer
Clin. Cancer Res., September 1, 2004; 10(17): 5754 - 5761.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Crown, M. O'Leary, and W.-S. Ooi
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
Oncologist, June 2, 2004; 9(suppl_2): 24 - 32.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, D. A. Berry, S. Woolf, D. Duggan, A. Kornblith, L. N. Harris, R. A. Michaelson, J. A. Kirshner, G. F. Fleming, M. C. Perry, et al.
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
J. Clin. Oncol., June 1, 2004; 22(11): 2061 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Polee, A. Sparreboom, F. A. L. M. Eskens, R. Hoekstra, J. van de Schaaf, J. Verweij, G. Stoter, and A. van der Gaast
A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer
Clin. Cancer Res., March 15, 2004; 10(6): 1928 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Colomer, A. Llombart-Cussac, A. Lluch, A. Barnadas, B. Ojeda, V. Caranana, Y. Fernandez, J. Garcia-Conde, S. Alonso, S. Montero, et al.
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain
Ann. Onc., February 1, 2004; 15(2): 201 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Advani, G. A. Fisher, B. L. Lum, C. Jambalos, C. D. Cho, M. Cohen, A. Gollerkeri, and B. I. Sikic
Phase I and Pharmacokinetic Study of BMS-188797, a New Taxane Analog, Administered on a Weekly Schedule in Patients with Advanced Malignancies
Clin. Cancer Res., November 1, 2003; 9(14): 5187 - 5194.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Sato, K. Inoue, T. Saito, T. Kai, H. Mihara, K. Okubo, J. Koh, H. Mochizuki, and T. Tabei
Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)
Jpn. J. Clin. Oncol., August 1, 2003; 33(8): 371 - 376.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Piccart-Gebhart
Mathematics and Oncology: A Match for Life?
J. Clin. Oncol., April 15, 2003; 21(8): 1425 - 1428.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. F. Kruijtzer, H. Boot, J. H. Beijnen, H. L. Lochs, F. X. Parnis, A. S. T. Planting, J. M. G. Pelgrims, R. Williams, R. A. A. Mathot, H. Rosing, et al.
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
Ann. Onc., February 1, 2003; 14(2): 197 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes
Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study
Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.M.F. Kruijtzer, J.H.M. Schellens, J. Mezger, M.E. Scheulen, U. Keilholz, J.H. Beijnen, H. Rosing, R.A.A. Mathot, S. Marcus, H. van Tinteren, et al.
Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., December 1, 2002; 20(23): 4508 - 4516.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. O'Shaughnessy, C. Twelves, and M. Aapro
Treatment for Anthracycline-Pretreated Metastatic Breast Cancer
Oncologist, December 1, 2002; 7(90006): 4 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
O. Juan, A. Albert, F. Ordono, R. Casany, V. Caranana, J. M. Campos, and V. Alberola
Low-dose Weekly Paclitaxel as Second-line Treatment for Advanced Non-small Cell Lung Cancer: a Phase II Study
Jpn. J. Clin. Oncol., November 1, 2002; 32(11): 449 - 454.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Loesch, N. Robert, L. Asmar, M. A. Gregurich, M. O'Rourke, S. Dakhil, and E. Cox
Phase II Multicenter Trial of a Weekly Paclitaxel and Carboplatin Regimen in Patients With Advanced Breast Cancer
J. Clin. Oncol., September 15, 2002; 20(18): 3857 - 3864.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Modi, K. S. Panageas, E. T. Duck, A. Bach, N. Weinstock, J. Dougherty, L. Cramer, C. Hudis, L. Norton, and A. Seidman
Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2002; 20(17): 3665 - 3673.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. K. Rowinsky
Taxane Analogues: Distinguishing Royal Robes from the "Emperor's New Clothes"
Clin. Cancer Res., September 1, 2002; 8(9): 2759 - 2763.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. U. Buzdar, S. E. Singletary, V. Valero, D. J. Booser, N. K. Ibrahim, Z. Rahman, R. L. Theriault, R. Walters, E. Rivera, T. L. Smith, et al.
Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer: Preliminary Data of a Prospective Randomized Trial
Clin. Cancer Res., May 1, 2002; 8(5): 1073 - 1079.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Aihara, Y. Kim, and Y. Takatsuka
Phase II study of weekly docetaxel in patients with metastatic breast cancer
Ann. Onc., February 20, 2002; 13(2): 286 - 292.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Vaughn, C. M. Broome, M. Hussain, J. C. Gutheil, and A. B. Markowitz
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
J. Clin. Oncol., February 15, 2002; 20(4): 937 - 940.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Gelderblom, K. Mross, A. J. ten Tije, D. Behringer, S. Mielke, D. M. van Zomeren, J. Verweij, and A. Sparreboom
Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions
J. Clin. Oncol., January 15, 2002; 20(2): 574 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Fidias, J. G. Supko, R. Martins, A. Boral, R. Carey, M. Grossbard, G. Shapiro, P. Ostler, J. Lucca, B. E. Johnson, et al.
A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., December 1, 2001; 7(12): 3942 - 3949.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Perez, C. L. Vogel, D. H. Irwin, J. J. Kirshner, and R. Patel
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
J. Clin. Oncol., November 15, 2001; 19(22): 4216 - 4223.
[Abstract] [Full Text]

Home page
 Jpn J Clin OncolHome page
S. Ota, T. Sugiyama, K. Komai, N. Hirai, S. Kumagai, K. Ushijima, T. Nishida, and T. Kamura
Weekly 1 Hour Paclitaxel Infusion in Patients with Recurrent Gynecological Tumors: a Pilot Study
Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 395 - 398.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, H. A. Burris III, D. A. Yardley, J. E. Bradof, M. Grimaldi, L. A. Kalman, T. Sullivan, M. Baker, J. B. Erland, and F. A. Greco
Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial
J. Clin. Oncol., August 1, 2001; 19(15): 3500 - 3505.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Baselga and J. M. Tabernero
Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy
Oncologist, June 1, 2001; 6(2008): 26 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. D. Seidman, M. N. Fornier, F. J. Esteva, L. Tan, S. Kaptain, A. Bach, K. S. Panageas, C. Arroyo, V. Valero, V. Currie, et al.
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
J. Clin. Oncol., May 15, 2001; 19(10): 2587 - 2595.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. K. Kelly, T. Curley, S. Slovin, G. Heller, J. McCaffrey, D. Bajorin, A. Ciolino, K. Regan, M. Schwartz, P. Kantoff, et al.
Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer
J. Clin. Oncol., January 1, 2001; 19(1): 44 - 53.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bellmunt, V. Guillem, L. Paz-Ares, J. L. Gonzalez-Larriba, J. Carles, E. Batiste-Alentorn, A. Saenz, M. Lopez-Brea, A. Font, M. Nogue, et al.
Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium
J. Clin. Oncol., September 18, 2000; 18(18): 3247 - 3255.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano, A. O'Neill, P. L. Schaefer, C. I. Falkson, and W. C. Wood
Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196
J. Clin. Oncol., June 12, 2000; 18(12): 2369 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Browder, C. E. Butterfield, B. M. Kräling, B. Shi, B. Marshall, M. S. O’Reilly, and J. Folkman
Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer
Cancer Res., April 1, 2000; 60(7): 1878 - 1886.
[Abstract] [Full Text]

Home page
 JCOHome page
H. J. Burstein, J. Manola, J. Younger, L. M. Parker, C. A. Bunnell, R. Scheib, U. A. Matulonis, J. E. Garber, K. D. Clarke, L. N. Shulman, et al.
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
J. Clin. Oncol., March 13, 2000; 18(6): 1212 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Paridaens, L. Biganzoli, P. Bruning, J. G. M. Klijn, T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, et al.
Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over
J. Clin. Oncol., February 14, 2000; 18(4): 724 - 724.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Kuter
Breast Cancer Highlights
Oncologist, August 1, 1999; 4(4): 299 - 308.
[Full Text]

Home page
 The OncologistHome page
E. A. Perez
Paclitaxel in Breast Cancer
Oncologist, December 1, 1998; 3(6): 373 - 389.
[Abstract] [Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online